{"id":"https://openalex.org/W4362533990","doi":"https://doi.org/10.1158/1535-7163.22499197","title":"Supplementary Figure 7 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib","display_name":"Supplementary Figure 7 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362533990","doi":"https://doi.org/10.1158/1535-7163.22499197"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.22499197","doi":"https://doi.org/10.1158/1535-7163.22499197","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22499197","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_7_from_Dacomitinib_PF-00299804_an_Irreversible_Pan-HER_Inhibitor_Inhibits_Proliferation_of_HER2-Amplified_Breast_Cancer_Cell_Lines_Resistant_to_Trastuzumab_and_Lapatinib/22499197/1/files/39957577.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_7_from_Dacomitinib_PF-00299804_an_Irreversible_Pan-HER_Inhibitor_Inhibits_Proliferation_of_HER2-Amplified_Breast_Cancer_Cell_Lines_Resistant_to_Trastuzumab_and_Lapatinib/22499197/1/files/39957577.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054528392","display_name":"Ondrej Kalous","orcid":"https://orcid.org/0000-0002-3821-6603","observed_orcids":["https://orcid.org/0000-0002-3821-6603"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ondrej Kalous","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045387212","display_name":"Dylan F. Conklin","orcid":"https://orcid.org/0000-0003-4708-0071","observed_orcids":["https://orcid.org/0000-0003-4708-0071"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dylan Conklin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009971985","display_name":"Amrita J. Desai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amrita J. Desai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028010756","display_name":"Neil A. O\u2019Brien","orcid":"https://orcid.org/0000-0001-7408-1091","observed_orcids":["https://orcid.org/0000-0001-7408-1091"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neil A. O'Brien","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104110850","display_name":"Charles Ginther","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Charles Ginther","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Lee Anderson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lee Anderson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114257754","display_name":"David J. Cohen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David J. Cohen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052493398","display_name":"Carolyn D. Britten","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carolyn D. Britten","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Ian Taylor","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ian Taylor","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074923974","display_name":"James G. Christensen","orcid":"https://orcid.org/0000-0003-1835-0335","observed_orcids":["https://orcid.org/0000-0003-1835-0335"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James G. Christensen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015491002","display_name":"Dennis J. Slamon","orcid":"https://orcid.org/0000-0002-6330-498X","observed_orcids":["https://orcid.org/0000-0002-6330-498X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dennis J. Slamon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5073989429","display_name":"Richard S. Finn","orcid":"https://orcid.org/0000-0003-2494-2126","observed_orcids":["https://orcid.org/0000-0003-2494-2126"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard S. Finn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dacomitinib","display_name":"dacomitinib","score":1.0},{"id":"https://openalex.org/keywords/her2-amplified-breast-cancer","display_name":"HER2-amplified breast cancer","score":0.925000011920929},{"id":"https://openalex.org/keywords/trastuzumab-resistance","display_name":"trastuzumab resistance","score":0.9779999852180481},{"id":"https://openalex.org/keywords/lapatinib-resistance","display_name":"lapatinib resistance","score":1.0},{"id":"https://openalex.org/keywords/protein-expression","display_name":"protein expression","score":0.7210000157356262},{"id":"https://openalex.org/keywords/cell-proliferation","display_name":"cell proliferation","score":0.5270000100135803},{"id":"https://openalex.org/keywords/drug-resistant-cell-lines","display_name":"drug-resistant cell lines","score":0.6370000243186951}],"concepts":[{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.9852885007858276},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.9579522609710693},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.48447227478027344},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.45962396264076233},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40852606296539307},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40688636898994446},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3879837989807129},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.32292163372039795},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2971928119659424}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.22499197","doi":"https://doi.org/10.1158/1535-7163.22499197","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22499197","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_7_from_Dacomitinib_PF-00299804_an_Irreversible_Pan-HER_Inhibitor_Inhibits_Proliferation_of_HER2-Amplified_Breast_Cancer_Cell_Lines_Resistant_to_Trastuzumab_and_Lapatinib/22499197/1/files/39957577.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1535-7163.22499197.v1","doi":"https://doi.org/10.1158/1535-7163.22499197.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22499197.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22499197","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_7_from_Dacomitinib_PF-00299804_an_Irreversible_Pan-HER_Inhibitor_Inhibits_Proliferation_of_HER2-Amplified_Breast_Cancer_Cell_Lines_Resistant_to_Trastuzumab_and_Lapatinib/22499197","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.22499197","doi":"https://doi.org/10.1158/1535-7163.22499197","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1535-7163.22499197","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_7_from_Dacomitinib_PF-00299804_an_Irreversible_Pan-HER_Inhibitor_Inhibits_Proliferation_of_HER2-Amplified_Breast_Cancer_Cell_Lines_Resistant_to_Trastuzumab_and_Lapatinib/22499197/1/files/39957577.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.8371999859809875,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4362533990.pdf","grobid_xml":"https://content.openalex.org/works/W4362533990.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2153343658","https://openalex.org/W4362492627","https://openalex.org/W2563504190","https://openalex.org/W1967506091","https://openalex.org/W2951416494","https://openalex.org/W1597931794","https://openalex.org/W2585923853","https://openalex.org/W2498025682","https://openalex.org/W2333239605","https://openalex.org/W2077609445"],"abstract_inverted_index":{"PDF":[0],"file,":[1],"247K,":[2],"The":[3],"effects":[4],"of":[5],"dacomitinib":[6],"on":[7],"protein":[8],"expression":[9],"in":[10],"lines":[11],"resistant":[12],"to":[13],"trastuzumab":[14],"and":[15],"lapatinib.":[16]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-06T00:00:00"}